Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

FDA Green Lights Companion Diagnostic for Avapritinib in Gastrointestinal Stromal Tumors

August 8th 2023

The FDA has approved the therascreen PDGFRA RGQ PCR kit for use as a companion diagnostic, co-developed by Qiagen and Blueprint Medicines, to assist in the identification of patients with gastrointestinal stromal tumors who may be candidates to receive avapritinib.

Dr Danish on the Potential Use of SCINTIX Radiation Technology in Bone and Lung Tumors

August 2nd 2023

Adnan F. Danish, MD, discusses the methodologies behind the use of SCINTIX radiation technology in metastatic bone and lung tumors, detailing how this technology differs from computed tomography or magnetic resonance imaging scans prior to treatment.

Molecular Testing Drives Progress in CRC

July 31st 2023

Emerging strategies leveraging biomarker data for the treatment of patients with early-stage and metastatic colorectal cancer have made precision medicine a top-of-mind topic for gastrointestinal oncologists.

Dr Bazhenova on Potential Combination Strategies With KRAS G12C Inhibitors in Advanced NSCLC

July 29th 2023

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Dr Husain on Developments in ALK+ NSCLC

July 29th 2023

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Examining the Promise of Multicancer Early Detection Tests: Looking to the Future

July 26th 2023

In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.

FDA Approves Companion Diagnostic for Quizartinib in FLT3-ITD+ AML

July 24th 2023

The FDA has approved the LeukoStrat CDx FLT3 Mutation Assay for use as a companion diagnostic to select patients with FLT3-ITD–positive acute myeloid leukemia who may be eligible to receive treatment with quizartinib (Vanflyta).1

Dr Johnson on ABBV-011 in Small Cell Lung Cancer

July 20th 2023

Melissa L. Johnson, MD, discusses the development of the seizure-related homolog protein 6–targeting antibody-drug conjugate ABBV-011 and outcomes with this agent in patients with small cell lung cancer.

Dr Danish on the Use of SCINTIX Radiation Technology in Metastatic Bone and Lung Tumors

July 20th 2023

Adnan F. Danish, MD, discusses the use of SCINTIX radiation technology in metastatic bone and lung tumors.

Examining the Promise of Multicancer Early Detection Tests: Takeaways From the ECLIPSE Trial

July 19th 2023

In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.

Dr Danish on the Challenges of Radiation Treatment in Lung and Bone Cancers

July 17th 2023

Adnan F. Danish, MD, discusses unmet needs in the treatment of patients with lung and bone cancers, and how unmet needs within this patient population are being addressed with the utilization of SCINTIX radiation technology.

Dr Danish on the Use of Novel Radiotherapy Approaches in Cancer Care

July 13th 2023

Adnan F. Danish, MD, discusses the use of novel radiotherapy approaches in cancer care.

Novel Radiotherapy Supports Precision Medicine Advances in Lung and Bone Cancers

July 13th 2023

Adnan F. Danish, MD, discusses current unmet needs in the treatment of patients with stage IV lung and bone cancers, the benefits SCINTIX technology can provide for these patients, and how John Theurer Cancer Center plans to use this technology to improve patient outcomes and support further radiation therapy research.

Examining the Promise of Multicancer Early Detection Tests: Lessons Learned From PATHFINDER

July 12th 2023

In this fifth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, walk through the key lessons learned from the prospective, multicenter PATHINDER study (NCT04241796), which evaluated a multicancer early detection test developed by GRAIL.

Paxalisib Plus Radiation Earns FDA Fast Track Status for PI3K+ Solid Tumor Brain Metastases

July 7th 2023

The FDA has granted a fast track designation to paxalisib in combination with radiation therapy for the treatment of patients with solid tumor brain metastases harboring PI3K pathway mutations.

Ixabepilone Generates Clinical Benefit in Patients With Metastatic Breast Cancer Selected by Companion Diagnostic

July 6th 2023

Ixabepilone produced clinical benefit in patients with metastatic breast cancer selected for treatment with the DRP®-IXEMPRA® companion diagnostic candidate.

Examining the Promise of Multicancer Early Detection Tests: Existing Concerns

July 5th 2023

In this fourth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss existing concerns regarding multicancer early detection tests.

Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases

July 5th 2023

Adagrasib has demonstrated intracranial activity among patients with KRAS G12C–mutated non–small cell lung cancer with untreated central nervous system metastases.

Examining LIFU–Aided Liquid Biopsy in Glioblastoma: Excitement Surrounding Focused Ultrasound Waves

July 4th 2023

In this last episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, shed light on the excitement surrounding the use of low-intensity focused ultrasound in cancer and other conditions.

FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer

June 30th 2023

The FDA has granted breakthrough therapy designation to zenocutuzumab for use as a potential therapeutic option in patients with advanced unresectable or metastatic NRG1 fusion–positive pancreatic cancer after disease progression on previous systemic therapy or who have no satisfactory alternative options available.